NEFL and myeloid sarcoma: This indicates that serum and/or CSF anti-NF-L, NF-M, and NF-H antibodies might be a potential a marker of CNS tissue damage in MS, but their potential predictive value for the future disease course, disability, disease progression, and treatment response needs to be investigated.